Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD3/CD19/CD20 trispecific antibody 1A46

A trispecific immunoglobulin G (IgG)-like T-cell engaging antibody targeting the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD3/CD19/CD20 trispecific antibody 1A46 binds to CD19- and/or CD20-expressing tumor B cell and CD3 antigen on cytotoxic T lymphocytes (CTLs). This activates and redirects CTLs to CD19- and/or CD20-expressing tumor cells, resulting in CTL-mediated killing of tumor cells. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD3/anti-CD19/anti-CD20 trispecific antibody 1A46
anti-CD3/CD19/CD20 trispecific antibody CMG1A46
CD19/CD20-targeting T-cell-engaging tri-specific antibody CMG1A46
CD3/CD19/CD20 T-cell engager CMG1A46
Code name:1A46
CMG 1A46
CMG-1A46
CMG1A46
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search